Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Once-daily versus twice-daily Orfadin (nitisinone) dosing in hereditary tyrosinemia type 1
2013-004132-29Phase 3Completed
- Sponsor
- Sobi
- Start
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of nitisinone in Fumarylacetoacetase deficiency (HT1), sponsored by Sobi. Primary endpoint: Minimum (Cmin) serum concentration of nitisinone. Started Aug 2014; status: completed.
02
Drugs
nitisinone
03
Conditions
Fumarylacetoacetase deficiency (HT1)
Beyond the preview
Go deeper on 2013-004132-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004132-29.